Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by Dual-antibody ADC Drug RC288 for Injection

About this update from Remegen Co. Ltd. Class A

Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by Dual-antibody ADC Drug RC288 for Injection The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Remegen Co. Ltd. Class A